Enhancing Recovery from Gut Microbiome Dysbiosis and Alleviating DSS-Induced Colitis in Mice with a Consortium of Rare Short-Chain Fatty Acid-Producing Bacteria

Achuthan Ambat,Linto Antony,Abhijit Maji,Sudeep Ghimire,Samara Mattiello,Purna C. Kashyap,Sunil More,Vanessa Sebastian,Joy Scaria

DOI: https://doi.org/10.1101/2023.09.11.556543

2024-02-26

Abstract:The human gut microbiota is a complex community comprising hundreds of species, with a few present in high abundance and the vast majority in low abundance. The biological functions and effects of these low-abundant species on their hosts are not yet fully understood. In this study, we assembled a bacterial consortium (SC-4) consisting of , and , which are low-abundant, short-chain fatty acid (SCFA)-producing bacteria isolated from healthy human gut, and tested its effect on host health using germfree and human microbiota-associated colitis mouse models. The selection also favored these four bacteria being reduced in abundance in either Ulcerative Colitis (UC) or Crohn’s disease (CD) metagenome samples. Our findings demonstrate that SC-4 can colonize germ-free (GF) mice, increasing mucin thickness by activating MUC-1 and MUC-2 genes, thereby protecting GF mice from Dextran Sodium Sulfate (DSS)-induced colitis. Moreover, SC-4 aided in the recovery of human microbiota-associated mice from DSS-induced colitis, and intriguingly, its administration enhanced the alpha diversity of the gut microbiome, shifting the community composition closer to control levels. The results showed enhanced phenotypes across all measures when the mice were supplemented with Inulin as a dietary fiber source alongside SC-4 administration. We also showed a functional redundancy existing in the gut microbiome, resulting in the low abundant SCFA producers acting as a form of insurance, which in turn accelerates recovery from the dysbiotic state upon the administration of SC-4. SC-4 colonization also upregulated iNOS gene expression, further supporting its ability to produce an increasing number of goblet cells. Collectively, our results provide evidence that low-abundant SCFA-producing species in the gut may offer a novel therapeutic approach to IBD.

Microbiology

What problem does this paper attempt to address?

This paper attempts to address the role of low-abundance short-chain fatty acid (SCFA)-producing bacteria in the gut microbiome and their potential in the treatment of inflammatory bowel disease (IBD).

Specifically, the researchers selected 4 low-abundance but SCFA-producing bacteria (particularly butyrate) from the healthy human gut and constructed a bacterial consortium (SC-4). Through experiments with germ-free mice and human microbiota-associated mouse models, the study aims to verify whether these low-abundance strains can:

1. **Colonize the gut**: The study found that SC-4 could successfully colonize germ-free mice, and 3 of the bacteria could also be detected in human microbiota-associated mice.
2. **Improve gut barrier function**: Colonization by SC-4 increased mucus thickness and activated the expression of MUC-1 and MUC-2 genes, thereby protecting germ-free mice from dextran sulfate sodium (DSS)-induced colitis.
3. **Promote recovery from disease state**: SC-4 helped human microbiota-associated mice recover from DSS-induced colitis and increased the α-diversity of the gut microbiome, making its composition closer to control levels.
4. **Synergize with dietary fiber**: When supplemented with inulin as dietary fiber, the effect of SC-4 was further enhanced, showing better improvement in disease phenotype.
5. **Act as a functional redundancy mechanism**: The study also indicated that there is functional redundancy in the gut microbiome, and low-abundance SCFA-producing bacteria can act as "insurance species" to accelerate recovery from dysbiosis.

In summary, this paper explores the potential application value of low-abundance SCFA-producing bacteria in maintaining gut health and treating IBD.